Hunt Hazel
Known title: Chief Scientific OfficerCIK: 0001698307
Associated companies
Transaction History
| CORT | ▲ Buy | Option Exercise | 150,000 | $582K | 2/9/2026 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 77,968 | $3.2M | 2/9/2026 | View on chart |
| CORT | ▲ Buy | Option Exercise | 150,000 | $494K | 2/11/2025 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 85,176 | $5.8M | 2/11/2025 | View on chart |
| CORT | ▲ Buy | Option Exercise | 60,000 | $169K | 8/1/2024 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 34,773 | $1.3M | 8/1/2024 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 29,792 | $818K | 1/8/2024 | View on chart |
| CORT | ▲ Buy | Option Exercise | 50,000 | $151K | 1/8/2024 | View on chart |
| CORT | ▼ Sell | Open Market | 20,455 | $632K | 8/14/2023 | View on chart |
| CORT | ▲ Buy | Option Exercise | 50,000 | $151K | 8/8/2023 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 29,545 | $901K | 8/8/2023 | View on chart |
| CORT | ▲ Buy | Option Exercise | 50,000 | $104K | 9/28/2022 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 29,997 | $781K | 9/28/2022 | View on chart |
| CORT | ▲ Buy | Option Exercise | 40,000 | $133K | 1/26/2022 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 25,350 | $435K | 1/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CORT Featured in Low-Beta Healthcare Stock List
Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.
CORT Featured in Low-Beta Healthcare Stock List. Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.